The research and production company Microkhim, which is the only Ukrainian manufacturer of a generic drug intended for the treatment of pulmonary arterial hypertension, has declared its readiness to provide free specialized medicines to all patients with this serious disease. In this regard, “MICROKHIM” calls on medical institutions to cooperate in the implementation of this program.
The Ukrainian state has taken on the burden of providing patients with pulmonary arterial hypertension, and the public procurement procedure is used as a tool for such support. However, currently in Ukraine, due to quarantine restrictions, public procurement is temporarily not conducted. As a result, for several months now, patients with pulmonary arterial hypertension have not been provided with an effective drug that can significantly extend the full life of patients with this disease.
“In such conditions,” MICROKHIM “considers it necessary to come to the aid of patients with pulmonary arterial hypertension and on a free basis to transfer to medical institutions, on the basis of which this category of persons is treated, the required amount of drug “NO-LAG”. In this regard, the company urges the heads of medical institutions to timely inform about the amount of drug “NO-LAG”, which will be needed for the treatment of such patients and agree on the procedure for transferring LLC NVF “MICROKHIM” the required amount of drug “- emphasizes Igor Pogromsky.
At the same time, MICROKHIM has many years of positive experience of cooperation with medical institutions in the implementation of charitable initiatives. In particular, only since the beginning of this year the company has already transferred charitable assistance to the Institute of Cardiology named after Academician N.D. Strazhesko NAMS of Ukraine in the form of the declared required amount of drug for the treatment of pulmonary arterial hypertension. This allowed to “cover” the annual need of patients undergoing treatment in the department of symptomatic hypertension of the institution, in specialized drugs based on sildenafil. Similar cooperation has been built on an ongoing basis with a number of medical institutions across the country.